Ocugen

Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …

Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More
Virpax Pharmaceuticals

Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that Matthew Barnes, the company’s senior director of portfolio management, will be presenting at the Outsourcing in Clinical Trials (OCT) Conference. …

Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference Read More